Immunology Investor Event
The Leading Immunology brand
in Specialty Respiratory
U.S. monthly respiratory NBRx¹
3,500
Feb 2020
COVID19
Jan 2022
sanofi
DUPIXENT
(dupilumab)
IgE
IL-5s
Outstanding performance
34
-
-
19% Asthma 12Y+ biologic
penetration²
5% Asthma 6-11Y biologic
penetration²
#1 Asthma NBRX share
(28%) QTD Q1'22³
#1 in Asthma new patient
share in Germany (31%)4
#1 total Asthma patients
share 28% and new patient
share 36% in Japan5
Potential best-in-disease Type 2
Asthma profile6 approved 6Y+
in U.S. & EU and 12Y+ in JP
1. IQVIA Custom US Monthly National Source of Business (Asthma, CRSWNP indications), Jan 22. 2. IQVIA Custom Monthly Patient Report, Jan'22 3. IQVIA Custom US Weekly
National Source of Business, 2/18/22 4. Germany IQVIA LRX-Database. DupixentⓇ asthma biologics market (naïve and switches) Source of Business, Observational period
01/2022. 5. Japan local ATU W13 Jan '22. 6. Type 2 phenotype: Eos ≥150 or FeNo ≥ 20 ppb, and/or OCS dependence. Leading Immunology Brand in US NBRx.
21 Immunology Investor Event
କ
First biologic approved in
CRSWNP in the U.S., EU, JP
and CAView entire presentation